Get started
GILEAD SCIENCESGILEAD SCIENCESGILEAD SCIENCES

GILEAD SCIENCES

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

GIS trade ideas

Gilead sciences - long term investmentDear traders and followers, It’s time again for one of our popular stock analytics. Today we take a closer look at Gilead Sciences The California-based pharmaceutical and biotechnology company offers a very attractive mix of Corona’s special economy, a bit of takeover fantasy and a moderate evaluation. The drug Remdesivir, which is approved for Corona treatment, is expected to generate sales of almost two billion dollars this year, which according to Bloomberg’s 2021 estimate should increase by another 20 percent. The 2021 KGV of eleven is among the ten lowest in the entire Nasdaq 100. No wonder there is speculation that AstraZeneca wants to take over Gilead, given that both groups are complementary in their focus areas. If this is not enough as a reason to buy, the share traded around 40 percent below the record high looks at the nice lower reversal, which can be seen in the chart picture along with the medium-term upward trend. Technical view: Market has formed a triangle formation since 2014 (after a strong up rally) and broke out of it at the beginning of March. The price is atm within correction movement which is expected to end at the drawn buy area at around 70 $. We´ve set our buy orders at this point. Feel free to leave a comment or to share your ideas in the comments section Please hit the like button if you share or like this idea. Thanks for your support !
NASDAQ:GILDLong
by DK_Investment
8
Swing trade idea on Gilead SciencesI don't actually like Gilead Sciences for a long-term buy and hold, because its earnings have been in a long-term downtrend. There's a case to be made for a swing trade, however. Gilead is now sitting on trend line support in a fairly high-volume range. It's about 25% below its median forward P/E and forward P/S for the last three years. It has been selling off on news that remdesivir has shown no therapeutic value for Covid-19, but it may now rally for a while on news that the FDA has approved it for emergency use in moderate Covid patients anyway.
NASDAQ:GILDLong
by ChristopherCarrollSmith
1